Adoptive Immuntherapie der akuten ADV-Infektion nach allogener Knochenmark- oder peripherer Blutstammzelltransplantation - ÎAKS

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-001092-35-DE

Enrollment

Registered

2006-01-26

Start date

2006-11-08

Completion date

Unknown

Last updated

2025-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenovirus infection following allogeneic stem cell transplantation.

Interventions

Product Name: CD3+ T-Cells Pharmaceutical Form: Intravenous infusion

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adenovirus infection following allogeneic stem cell transplantation. Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: GvHD III-IV at the time of T-cell transfer.

Design outcomes

Primary

Measure	Time frame
Main Objective: Safety of adoptive transfer of virus specific T-cells from the donor of the allogeneic stem cell transplantation.;Secondary Objective: Initial evidence of the efficacy using adoptive transfer of virus specific T-cells from the donor of the allogeneic stem cell transplantation.;Primary end point(s): Evaluable safety data on 20-30 patients.	—

Countries

Germany

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026